December 2024
Protego Bio Raises $130 Million Oversubscribed Series B Financing
Protego Bio announced the completion of a $130 million oversubscribed
Series B financing to advance PROT-001, our first-in-class AL amyloidosis
program, into pivotal clinical studies. The financing round demonstrates
strong investor confidence in our scientific approach and clinical strategy.
"This significant investment enables us to advance PROT-001 through pivotal
development and brings us closer to delivering a transformative therapy for
patients with AL amyloidosis," said Brent Warner, Chief Executive Officer.
Read Full Press Release
November 2021
Protego Bio Raises $51 Million Series A Financing
Protego Bio announced the completion of a $51 million Series A financing
to advance the treatment of protein misfolding diseases. The financing was
led by premier healthcare investors and will support the advancement of our
lead programs and expansion of our discovery pipeline.
The Series A financing enables Protego to build on the validated mechanism
of pharmacological chaperones, extending this proven approach to new
therapeutic targets with significant unmet medical need.
Read Full Press Release
Company Update
PROT-001 Program Update: Advancing Toward Pivotal Studies
Our lead program, PROT-001, continues to advance through clinical development
for the treatment of AL (light chain) amyloidosis. PROT-001 is designed to
bind to and stabilize light chain proteins, preventing their misfolding and
toxic accumulation as amyloid deposits in vital organs.
AL amyloidosis is a devastating rare disease with limited treatment options.
We believe PROT-001 has the potential to become a first-in-class therapy that
addresses the underlying cause of disease by stabilizing the misfolded protein.
Research & Development
Expanding Our Pipeline: New Programs in Protein Misfolding Diseases
Beyond our lead AL amyloidosis program, we continue to expand our pipeline
of pharmacological chaperones targeting protein misfolding diseases. Our
discovery platform is generating promising candidates for additional
indications including cardiomyopathy, myopathy, and degenerative diseases.
Our approach builds on the proven success of tafamidis, discovered by our
cofounders, and extends this validated mechanism to new targets with
significant unmet medical need.
Team & Culture
Building a World-Class Team in San Diego
Protego Bio continues to attract top talent from leading biotechnology
companies and academic institutions. Our team brings deep expertise in
protein biology, medicinal chemistry, clinical development, and translational
medicine.
We're proud to foster a collaborative culture that values scientific
excellence, innovation, and a shared commitment to transforming the lives
of patients with protein misfolding diseases.
Join Our Team